<DOC>
	<DOCNO>NCT00057616</DOCNO>
	<brief_summary>Subjects randomize one two treatment arm . All subject screen eligibility within 28 day prior randomization . The study consist treatment phase follow-up phase . Subjects treat repeat 4 week cycle .</brief_summary>
	<brief_title>Study Compare Efficacy Safety CC-5013 v . Placebo Subjects With Metastatic Malignant Melanoma .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement Metastatic malignant melanoma stage IV , relapse refractory standard metastatic therapy Women childbearing potential must negative serum urine pregnancy test within 7 day start study drug Patients active brain disease , newly diagnose brain metastasis , within 4 week prior start study treatment exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
</DOC>